Issues
-
Cover Image
Cover Image
Invasive lobular carcinoma of the breast (ILC) is the most common special subtype of breast cancer, and though nearly all ILC express estrogen receptor alpha (ERα), ILC represent a distinct context for ERα function among breast cancers. The cover depicts a stylized immunofluorescence image showing DNA damage foci to which Mediator of DNA Damage Checkpoint 1 (MDC1) has localized. MDC1 canonically acts in the DNA damage response. However, in their study on page 1270, Sottnik, Bordeaux, and colleagues provide evidence that MDC1 also has novel ERα co-regulator activity and is critical for ERα function in ILC cells. The authors argue that canonical functions of MDC1 in DNA repair may be superseded by novel ERα co-regulator activity in this context. Artwork by Kristine M. Sikora, PhD. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Molecular Cancer Research
Table of Contents
Highlights
Review
Cancer Genes and Networks
EGR1 Addiction in Diffuse Large B-cell Lymphoma
Cancer “-omics”
Genome Maintenance
Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor
R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
Metabolism
Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress
New Horizons in Cancer Biology
RNA Biology
Tumor Microenvironment and Immunobiology
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model
Corrections
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.